EDRAZEE
Composition (Each vial/ampoule contains):
Edaravone: 1.5 mg
Dosage Form: Sterile Injection
Route of Administration: Intravenous
Therapeutic Class: Free Radical Scavenger / Neuroprotective Agent
EDRAEE is a sterile Edaravone injection formulated to provide neuroprotection by neutralizing its harmful free radicals in the brain. EDRAZEE helps to limit neuronal damage caused by ischemia and oxidative injury, and supports better neurological outcomes. It is administered intravenously to allow rapid distribution and targeted action in cerebral tissue. Each vial contains 1.5 mg of Edaravone, a potent free radical scavenger which is known for reducing oxidative stress in acute neurological conditions. It is commonly used in hospital settings as a part of early intervention strategies for patients with acute and progressive neurological disorders under medical supervision.
EDRAEE is a sterile Edaravone injection formulated to provide neuroprotection by neutralizing its harmful free radicals in the brain. EDRAZEE helps to limit neuronal damage caused by ischemia and oxidative injury, and supports better neurological outcomes. It is administered intravenously to allow rapid distribution and targeted action in cerebral tissue. Each vial contains 1.5 mg of Edaravone, a potent free radical scavenger which is known for reducing oxidative stress in acute neurological conditions. It is commonly used in hospital settings as a part of early intervention strategies for patients with acute and progressive neurological disorders under medical supervision.
FAQ
Q: How does Edaravone work to reduce brain damage during ischemic events?
A: Edaravone neutralizes free radicals that trigger oxidative neuronal injury, which helps to preserve viable brain tissue.
Q: How does intravenous administration make EDRAZEE injection more effective in neutralizing free radicals in the brain?
A: It ensures controlled, rapid delivery and predictable therapeutic levels in critical neurological care, which ensures better therapeutic outcomes.
Q: What is the role of early administration for Edaravone therapy?
A: With early administration is helps to minimize the oxidative damage and improves neuroprotective outcomes.
Q: Does this injection work better when used alongside other thrombolytic agents for better results?
A: Yes, it is often used as adjunct therapy, based on the clinical requirement and patient condition.
Q: Are there any other benefits of Edaravone beyond stroke management?
A: Yes, it can be used to support neuroprotection in other oxidative stress-related neurological conditions.
Q: Is it safe to continue the administration of this injection for the long term?
A: Treatment duration will only be followed as per the healthcare professional's prescribed duration course. It is typically used for short-term and is determined by clinical protocols.
Q: Do EDAZEE injections affect cerebral blood circulation directly?
A: No, it does not alter blood flow directly, but it may protect neurons from oxidative damage.
Q: Does it require special monitoring during Endaravone therapy?
A: It may require monitoring for renal function and hypersensitivity reactions.
FAQ
Apply for PCD Franchise – Not for Job Queries
Apply for PCD Franchise – Not for Job Queries
